{"pub": "reuters", "url": "https://uk.reuters.com/article/uk-gsk-results/gsk-lifts-annual-profit-forecast-after-third-quarter-beat-idUKKBN1X91FO", "downloaded_at": "2019-10-30 12:32:23.972410+00:00", "title": "GSK lifts annual profit forecast after third-quarter beat", "language": "en", "text": "FILE PHOTO: The GlaxoSmithKline (GSK) logo on top of GSK Asia House is seen through vertical louvres in Singapore, March 21, 2018. REUTERS/Loriene Perera\n\n(Reuters) - GlaxoSmithKline Plc (GSK.L) on Wednesday raised its annual profit forecast for the second time this year as soaring sales of its Shingles vaccine helped offset a hit from generic competition to its blockbuster asthma drug Advair.\n\nThe drugmaker now expects full-year profit to be about flat compared to last year at constant currency, up from a previous forecast of a fall of 3% to 5%.\n\nTurnover rose 11% to \u00a39.39 billion in the three months ended Sept. 30, a year earlier, said GSK.\n\nAdjusted earnings were 38.6 pence per share.\n\nAnalysts on average had expected earnings of 33 pence and sales of \u00a39.02 billion, according to a company-compiled consensus here of 15 analysts.", "description": "GlaxoSmithKline Plc on Wednesday raised its annual profit forecast for the second time this year as soaring sales of its Shingles vaccine helped offset a hit from generic competition to its blockbuster asthma drug Advair.", "authors": ["Reuters Editorial", "Min Read"], "top_image": "https://s4.reutersmedia.net/resources/r/?m=02&d=20191030&t=2&i=1446522448&w=1200&r=LYNXMPEF9T0YX", "published_at": "2019-10-30"}